



MITHRA WILL PROPOSE CHRISTIANE MALCORPS AS NEW INDEPENDENT BOARD MEMBER / PHASE III CLINICAL STUDY FOR ESTELLE® IN US LAUNCHED WITH FIRST RANDOMIZED PATIENT

Liège, Belgium, 23rd September 2016 –Today, Mithra announces that Christiane Malcorps will be proposed as a new member of Mithra’s Board of Directors (Mithra SA) during the next Shareholders meeting. She also is appointed as member of the Board of Mithra’s CDMO (Development and production center).

Christiane Malcorps ir. PhD, is currently Country Manager for Belgium and Global Head of Facility Excellence for SOLVAY SA.

After receiving a Master in Chemical Engineering at KU Leuven and a PhD at the University of Wisconsin, Madison, USA, she occupied applied and fundamental research positions at different universities in USA and Belgium and entered SOLVAY S.A. in 1984. She was assigned within SOLVAY several Research, Development and Technology functions first with local and later on with international responsibilities in the fields of biopesticides, enzymes and vaccines. In 1997 she was based in the SOLVAY plants in Antwerp and became in 2005 Site Director of the Antwerp complex for SOLVAY producing polyolefines and chlorine. Always striving for excellence she became country manager for Belgium in 2009. During her career she was trained as executive in the business schools of INSEAD & IMD.

Christiane Malcorps is member of the Board of several professional and other organizations in Belgium (essenscia, UWE, BECI, The Shift, Degraeve Antwerpia).

Marc Coucke, President of the Board of Mithra Pharmaceuticals : *“We are pleased to welcome Christiane to Mithra’s Board of Directors, where she brings over 30 years of expertise in the industrial sector. Throughout her career Christiane Malcorps always kept a special attention for innovation and sustainable development to create value. We will greatly benefit from Christiane’s extensive experience in business management, as well in the Board as particularly for our CDMO.”*

Christiane Malcorps: *«I am very much looking forward to collaborate at the level of the board with the experienced team of Mithra, a dynamic and innovative company striving to develop, manufacture and commercialise drugs and complex generic products for women, improving their quality of life.»*

Liège, Belgium 23 rd September 2016 – Mithra announces today that the first patient has been randomized in the American Phase III clinical trials for its Estetrol-based product candidate Estelle® (E4/DRSP). The enrollment of this first patient marks the official launch of the Estelle® (E4/DRSP) Phase III clinical trial in United States. With this, the Phase III is fully in line with the timing and objectives announced in the Prospectus.

François Fornieri, CEO of Mithra Pharmaceuticals: *“This represents a significant step in the development of Estelle®, highlighting the work of our dedicated R&D and regulatory affairs teams. We are looking forward to further enrolling patients in United States. The Phase III clinical program will evaluate the contraceptive efficacy of Estelle® (E4/DRSP) in adult women. The trial launched in United States/Canada is aimed at enrolling 2000 patients aged from 16 to 50 year, who will receive Estelle® (E4/DRSP) during 12 months.”*

Pictures

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

For more information, please contact:

Press

Julie Dessart

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

press@mithra.com

Investor Relations

François Fornieri, CEO

+32 4 349 28 22

investorrelations@mithra.com

About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women’s Health. Mithra’s mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women’s health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women’s health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra's newsletter, visit investors.mithra.com